HP
HBM Partners
Venture CapitalActiveHBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies.
30
Investments
6
Exits
$4B
AUM
20.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for HBM Partners.
Investment Thesis & Strategy
HBM Partners invests in various stages of private and public emerging biopharma and healthcare-related companies, leveraging its expertise in the biotech, fintech, and life science sectors.
Investment Activity
Deals per year over the last 15 years
2
20080
20091
20100
20110
20120
20132
20141
20150
20161
20170
20181
20191
20201
20212
2022Portfolio Companies
Selected investments from their portfolio of 30 companies
G
GlycoEra
Biotech · Series A, 2022
A
Aurion Biotech
Biotech · Growth, 2022
K
Kinarus Therapeutics
Biotech · Growth, 2021
A
Achiko
Biotech · Growth, 2020
T
T3 Pharma
Biotech · Series A, 2019
I
Inositec
Biotech · Series A, 2017
O
ObsEva
Biotech · Series C+, 2015
A
AM-Pharma
Biotech · Series C+, 2014
B
BioVersys
Biotech · Series A, 2014
A
ADC Therapeutics
Biotech · Series C+, 2010
P
Polyphor
Biotech · Series C+, 2008
N
NovImmune
Biotech · Series C+, 2008
Notable Exits
CompanyTypeYearValue / Acquirer
ActelionAcquisition2017$30B
IdorsiaIPO2017—
ESBATechAcquisition2009—
Basilea PharmaceuticaIPO2007—
Addex TherapeuticsIPO2007—
ArpidaIPO2006—
Frequently Asked Questions
HBM Partners focuses on Series A, Series B, Series C+ stage investments.